中國神經(jīng)再生研究（英文版）》雜志于2012年7月19期出版的一項關(guān)于“Immunotherapy of rat glioma without accumulation of CD4+CD25+FOXP3+ regulatory T cells”的研究顯示，應(yīng)用全膠質(zhì)瘤細胞裂解物致敏樹突狀細胞,，聯(lián)合過繼性T細胞建立了一種新的免疫方法,。
接種后21d，聯(lián)合免疫的載瘤鼠腦腫瘤體積減小,，腫瘤內(nèi)特異性細胞毒性T淋巴細胞的細胞毒性反應(yīng)強烈,，外周血CD4+ CD25 + FOXP3+調(diào)節(jié)性T細胞比例明顯下降，存活時間延長,。
作者認為全膠質(zhì)瘤細胞裂解物致敏樹突狀細胞聯(lián)合過繼性T細胞可有效地抑制大鼠腦膠質(zhì)瘤的生長,，提高抗腫瘤能力,，也避免了CD4+ CD25 + FOXP3+調(diào)節(jié)性T細胞的積累，可為臨床治療惡性腦膠質(zhì)瘤提供強有力的免疫治療方案和科學(xué)依據(jù),。（生物谷Bioon.com）
doi:10.3969/j.issn.1673-5374
PMC:
PMID:
Immunotherapy of rat glioma without accumulation of CD4+ CD25+ FOXP3+ regulatory T cells
Enshan Feng1 , Haili Gao2 , Wei Su2 , Chunjiang Yu1
Immunotherapy may be used for the treatment of glioblastoma multiforme; however, the induced immune response is inadequate when either T cells or dendritic cells are used alone. In this study we established a novel vaccine procedure in rats, using dendritic cells pulsed with C6 tumor cell lysates in combination with adoptive transfer of T lymphocytes from syngenic donors. On day 21 after tumor inoculation, all the rats were sacrificed, the brains were harvested for calculation of glioma volume, cytolytic T lymphocyte responses were measured by cytotoxic assay, and the frequency of regulatory T lymphocytes (CD4+ CD25+ FOXP3+ ) in the peripheral blood was inves- tigated by flow cytometric analysis. The survival rate of rats bearing C6 glioma was observed. Results showed that the co-immunization strategy had significant anti-tumor potential against the pre-established C6 glioma, and induced a strong cytolytic T lymphocyte response in rats. The frequency of peripheral blood CD4+ CD25+ FOXP3+ regulatory T lymphocytes was significantly decreased following the combination therapy, and the rats survived for a longer period. Experi- mental findings indicate that the combined immunotherapy of glioma cell lysate-pulsed dendritic cell vaccination following adoptive transfer of T cells can effectively inhibit the growth of gliomas in rats, boost anti-tumor immunity and produce a sustained immune response while avoiding the accumulation of CD4+ CD25+ FOXP3+ regulatory T lymphocytes.
